CoChat

Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data

Open access
† · 2014 · The Lancet

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Individual participant data meta-analyses of postoperative chemotherapy have shown improved survival for patients with non-small-cell lung cancer (NSCLC). We aimed to do a systematic review and individual participant data meta-analysis to establish the effect of preoperative chemotherapy for patients with resectable NSCLC. METHODS: We systematically searched for trials that started after January, 1965. Updated individual participant data were centrally collected, checked, and analysed. Results from individual randomised controlled trials (both published and unpublished) were combined using a two-stage fixed-effect model. Our primary outcome, overall survival, was defined as the time from randomisation until death (any cause), with living patients censored on the date of last follow-up. Secondary outcomes were recurrence-free survival, time to locoregional and distant recurrence, cause-specific survival, complete and overall resection rates, and postoperative mortality. Prespecified analyses explored any variation in effect by trial and patient characteristics. All analyses were by intention to treat. FINDINGS: Analyses of 15 randomised controlled trials (2385 patients) showed a significant benefit of preoperative chemotherapy on survival (hazard ratio [HR] 0·87, 95% CI 0·78-0·96, p=0·007), a 13% reduction in the relative risk of death (no evidence of a difference between trials; p=0·18, I(2)=25%). This finding represents an absolute survival improvement of 5% at 5 years, from 40% to 45%. There was no clear evidence of a difference in the effect on survival by chemotherapy regimen or scheduling, number of drugs, platinum agent used, or whether postoperative radiotherapy was given. There was no clear evidence that particular types of patient defined by age, sex, performance status, histology, or clinical stage benefited more or less from preoperative chemotherapy. Recurrence-free survival (HR 0·85, 95% CI 0·76-0·94, p=0·002) and time to distant recurrence (0·69, 0·58-0·82, p<0·0001) results were both significantly in favour of preoperative chemotherapy although most patients included were stage IB-IIIA. Results for time to locoregional recurrence (0·88, 0·73-1·07, p=0·20), although in favour of preoperative chemotherapy, were not statistically significant. INTERPRETATION: Findings, which are based on 92% of all patients who were randomised, and mainly stage IB-IIIA, show preoperative chemotherapy significantly improves overall survival, time to distant recurrence, and recurrence-free survival in resectable NSCLC. The findings suggest this is a valid treatment option for most of these patients. Toxic effects could not be assessed. FUNDING: Medical Research Council UK.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(13)62159-5

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Effect of preoperative chemotherapy on survival Each square denotes the HR for that trial comparison with the horizontal lines showing the 95% and 99% CIs. The size of the square is directly proportional to the amount of information contributed by the trial. The black diamond gives the pooled HR from the fixed effect model; the centre of this diamond denotes the HR and the extremities the 95% CI. O–E=observed minus expected. HR=hazard ratio. MIP=mitomycin, ifosphamide, cisplatin. SWOG=South West Oncology Group. JCOG=Japanese Cancer Oncology Group. MRC=Medical Research Council. BLT=Big Lung Trial. ChEST=Chemotherapy for Early Stages Trial. NATCH=Neoadjuvant/Adjuvant Trial of Chemotherapy. df=degrees of freedom. *Number of events/number entered.
Figure 1 Effect of preoperative chemotherapy on survival Each square denotes the HR for that trial comparison with the horizontal lines showing the 95% and 99% CIs. The size of the square is directly proportional to the amount of information contributed by the trial. The black diamond gives the pooled HR from the fixed effect model; the centre of this diamond denotes the HR and the extremities the 95% CI. O–E=observed minus expected. HR=hazard ratio. MIP=mitomycin, ifosphamide, cisplatin. SWOG=South West Oncology Group. JCOG=Japanese Cancer Oncology Group. MRC=Medical Research Council. BLT=Big Lung Trial. ChEST=Chemotherapy for Early Stages Trial. NATCH=Neoadjuvant/Adjuvant Trial of Chemotherapy. df=degrees of freedom. *Number of events/number entered.CC BY · PubMed Central
Figure 2 Kaplan-Meier curves (non-stratified) of the effect of preoperative chemotherapy on time to survival
Figure 2 Kaplan-Meier curves (non-stratified) of the effect of preoperative chemotherapy on time to survivalCC BY · PubMed Central
Figure 3 Forest plot of the interactions between the effect of preoperative chemotherapy on survival and covariates The circles represent (fixed effect) meta-analyses of the HRs representing the interactions between the effect of chemotherapy and patient characteristics; the horizontal line shows the 95% CI. HR=hazard ratio.
Figure 3 Forest plot of the interactions between the effect of preoperative chemotherapy on survival and covariates The circles represent (fixed effect) meta-analyses of the HRs representing the interactions between the effect of chemotherapy and patient characteristics; the horizontal line shows the 95% CI. HR=hazard ratio.CC BY · PubMed Central
Figure 4 Kaplan-Meier curves (non-stratified) of the effect of preoperative chemotherapy on time to distant and locoregional recurrence and recurrence-free survival Analyses of recurrence outcomes were calculated from a landmark time of 6 months from the date of randomisation; for this reason time on the x-axis starts at 6 months.
Figure 4 Kaplan-Meier curves (non-stratified) of the effect of preoperative chemotherapy on time to distant and locoregional recurrence and recurrence-free survival Analyses of recurrence outcomes were calculated from a landmark time of 6 months from the date of randomisation; for this reason time on the x-axis starts at 6 months.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 47 references

Research works printed but not linked: 1

  1. Wu, 2002, Neo-adjuvant chemotherapy with docetaxel plus carboplatin for non-small cell lung cancer, Ann Oncol, 13, 140

Cited by

See all 976

Metadata

Authors
†
Corresponding author
†
Venue
The Lancet
Publisher
Elsevier BV
Published
2014-05
Volume
383
Issue
9928
Pages
1561-1571
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2182482244
Cited by
884
References
46
Citations by year
2026: 58 · 2025: 80 · 2024: 131 · 2023: 133 · 2022: 105 · 2021: 95 · 2020: 56 · 2019: 53 · 2018: 49 · 2017: 38 · 2016: 34 · 2015: 34 · 2014: 18
FWCI
7.07
Type
journal article
Language
en
Open access
Licence
Locations
  • The Lancet (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
  • UCL Discovery (University College London) (submittedVersion)
Funders
Institut Gustave-Roussy, Programme Hospitalier de Recherche Clinique (AOM 05 209)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
  • Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords
neoadjuvant chemotherapy, non-small cell lung cancer, resectable lung cancer, overall survival, recurrence-free survival, locoregional recurrence, distant recurrence, postoperative mortality, resection rate, platinum-based chemotherapy, postoperative radiotherapy, chemotherapy schedule, trial heterogeneity, publication bias
MeSH terms
Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Neoplasm Recurrence, Local, Preoperative Care, Randomized Controlled Trials as Topic, Treatment Outcome, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. https://app.cochat.ai/papers/10.1016/s0140-6736(13)62159-5
The paper
†. (2014). Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. The Lancet. https://doi.org/10.1016/s0140-6736(13)62159-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.